Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, First-in-human Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of AMX-500 in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Next Previous
Search
Trial Profile

A Phase 1, First-in-human Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of AMX-500 in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AMX 500 (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Amunix

    • Most Recent Events

    • 08 Jan 2025 Preliminary safety and efficacy results (n=18) presented in the Vir Biotechnology Media Release.
    • 09 Sep 2024 According to a Vir Biotechnology media release, the exclusive worldwide license agreement with Sanofi announced on August 1, 2024, has closed, providing Vir with an exclusive worldwide license to three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the proprietary PRO-XTENTM masking platform. The clinical-stage assets under the agreement are SAR446309, SAR446329 and SAR446368.
    • 01 Aug 2024 According to a Vir Biotechnology media release, Phase 1 monotherapy study data expected in the second half of 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top